Comparison of minichromosome maintenance proteins (MCM-3, MCM-7) and metallothioneins (MT-I/II, MT-III) expression in relation to clinicopathological data in ovarian cancer

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5375-5384

  Kobierzycki, Christopher ^a   Pula, Bartosz ^a,b   Skiba, Mateusz ^a   Jablonska, Karolina ^a   Latkowski, Krzysztof ^a   Zabel, Maciej ^a,c   Nowak Markwitz, Ewa ^c   Spaczynski, Marek ^c   Kedzia, Witold ^c   Podhorska Okolow, Marzena ^a   Dziegiel, Piotr ^a,d  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b 4th Department of Internal Medicine and Pulmonology   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d UNIVERSITY SCHOOL OF PHYSICAL EDUCATION   (Poland)

Author keywords

Metallothionein; Minichromosome maintenance protein; Ovarian cancer

Indexed keywords

KI 67 ANTIGEN; METALLOTHIONEIN I; METALLOTHIONEIN II; METALLOTHIONEIN III; MINICHROMOSOME MAINTENANCE PROTEIN 3; MINICHROMOSOME MAINTENANCE PROTEIN 7;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; COMPARATIVE STUDY; CYTOPLASM; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARIECTOMY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84891434742     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Hunn J and Rodriguez GC: Ovarian cancer: Etiology, risk factors, and epidemiology. Clin Obstet Gynecol 55: 3-23, 2012.
2. Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I and Salzet M: Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett 291: 59-66, 2010.
3. Gadducci A, Fuso L, Cosio S, Landoni F, Maggino T, Perotto S, Sartori E, Testa A, Galletto L and Zola P: Are surveillance procedures of clinical benefit for patients treated for ovarian cancer? A retrospective Italian multicentric study. Int J Gynecol Cancer 19: 367-374, 2009.
4. Labib K and Gambus A: A key role for the GINS complex at DNA replication forks. Trends Cell Biol 17: 271-278, 2007.
5. Forsburg SL: Eukaryotic MCM proteins: beyond replication initiation. Microbiol Mol Biol Rev 68: 109-131, 2004.
6. Gonzalez MA, Tachibana KE, Laskey RA and Coleman N: Control of DNA replication and its potential clinical exploitation. Nat Rev Cancer 5: 135-141, 2005.
7. 1-phase and are required to establish, but not maintain, the S-phase checkpoint. Mol Biol Cell 12: 3658-3667, 2001.
8. Wojnar A, Kobierzycki C, Krolicka A, Pula B, Podhorska-Okolow M and Dziegiel P: Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers. Folia Histochem Cytobiol 48: 442-446, 2010.
9. Gakiopoulou H, Korkolopoulou P, Levidou G, Thymara I, Saetta A, Piperi C, Givalos N, Vassilopoulos I, Ventouri K, Tsenga A, Bamias A, Dimopoulos MA, Agapitos E and Patsouris E: Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: Relationship with cell cycle regulators and prognostic implications. Br J Cancer 97: 1124-1134, 2007.
10. Kelly EJ, Quaife CJ, Froelick GJ and Palmiter RD: Metallothionein I and II protect against zinc deficiency and zinc toxicity in mice. J Nutr 126: 1782-1790, 1996.
11. Cherian MG and Goyer RA: Metallothioneins and their role in the metabolism and toxicity of metals. Life Sci 23: 1-8, 1978.
12. Inoue K, Takano H, Shimada A and Satoh M: Metallothionein as an anti-inflammatory mediator. Mediators Inflamm 2009: 1065, 2009.
13. Kondo Y, Rusnak JM, Hoyt DG, Settineri CE, Pitt BR and Lazo JS: Enhanced apoptosis in metallothionein null cells. Mol Pharmacol 52: 195-201, 1997.
14. Masters BA, Quaife CJ, Erickson JC, Kelly EJ, Froelick GJ, Zambrowicz BP, Brinster RL and Palmiter RD: Metallothionein III is expressed in neurons that sequester zinc in synaptic vesicles. J Neurosci 14: 5844-5857, 1994.
15. Quaife CJ, Findley SD, Ericson JC, Froelick GJ, Kelly EJ, Zambrowicz BP and Palmiter RD: Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified epithelia. Biochemistry 33: 7250-7259, 1994.
16. Cherian MG, Jayasurya A and Bay BH: Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 533: 201-209, 2003.
17. Dziegiel P: Expression of metallothioneins in tumor cells. Pol J Pathol 55: 3-12, 2004.
18. Gomulkiewicz A, Podhorska-Okolow M, Szulc R, Smorag Z, Wojnar A, Zabel M and Dziȩgiel P: Correlation between metallothionein (MT) expression and selected prognostic factors in ductal breast cancers. Folia Histochem Cytobiol 48: 242-248, 2010.
19. Haq F, Mahoney M and Koropatnick J: Signaling events for metallothionein induction. Mut Res 533: 211-226, 2003.
20. Pedersen MØ, Larsen A, Stoltenberg M, Penkowa M: The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem 44: 29-64, 2009.
21. Deng D, El-Rifai W, Ji J, Zhu B, Trampont P, Li J, Smith MF and Powel SM: Hypermethylation of metallothionein-3 CpG island in gastric carcinoma. Carcinogenesis 24: 25-29, 2003.
22. Smith E, Drew P, Tian Z, De Young N, Liu J, Mayne G, Ruszkiewicz A, Watson D and Jamieson G: Metallothionein 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation. Mol Cancer 4: 42, 2005.
23. Somji S, Garrrett SH, Zhou XD, Zheng Y, Sens DA and Sens MA: Absence of metallothionein 3 expression in breast cancer is a rare, but favorable marker of outcome that is under epigenetic control. Toxicol Environ Chem 92: 1673-1695, 2010.
24. Hoey JG, Garrett SH, Sens MA, Todd JH and Sens DA: Expression of MT-3 mRNA in human kidney, proximal tubule cell cultures, and renal cell carcinoma. Toxicol Lett 92: 149-160, 1997.
25. Surowiak P, Materna V, Maciejczyk A, Pudelko M, Markwitz E, Spaczynski M, Dietel M, Zabel M and Lage H: Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch 450: 279-285, 2007.
26. Dutta R, Sens DA, Somji S, Sens MA, Garrett SH: Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC-3 prostate cancer cells. Prostate 52: 89-97, 2002.
27. Sens MA, Somji S, Lamm DL, Garrett SH, Slovinsky F, Todd JH and Sens DA: Metallothionein isoform 3 as a potential biomarker for human bladder cancer. Environ Health Perspect 108: 413-418, 2000.
28. Sens MA, Somji S, Garrett SH and Sens DA: Metallothionein isoform 3 (MT-3) overexpression is associated with breast cancers having a poor prognosis. Am J Pathol 159: 21-26, 2001.
29. Garrett SH, Sens MA, Shukla D, Nestor S, Somji S, Todd JH and Sens DA: Metallothionein isoform 3 expression in the human prostate and cancer-derived cell lines. Prostate 41: 196-202, 1999.
30. Tavassoli FA and Devilee P: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumours. IARC Press, Lyon, 2003.
31. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancertissue. Pathologe 8: 138-140, 1987.
32. Levidou G, Ventouri K, Nonni A, Gakiopoulou H, Bamias A, Sotiropoulou M, Papaspirou I, Dimopoulos MA, Patsouris E and Korkolopoulou P: Replication protein A in nonearly ovarian adenocarcinomas: Correlation with MCM-2, MCM-5, Ki-67 index and prognostic significance. Int J Gynecol Pathol 31: 319-327, 2012.
33. Ota T, Clayton AC, Minot DM, Shridhar V, Hartmann LC, Gilks CB and Chien JR: Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. Mod Pathol 24: 277-287, 2011.
34. Facoetti A, Ranza E, Benericetti E, Ceroni M, Tedeschi F and Nano R: Minichromosome maintenance protein 7: A reliable tool for glioblastoma proliferation index. Anticancer Res 26: 1071-1075, 2006.
35. Kobierzycki C, Pula B, Wojnar A, Podhorska-Okolow M and Dziegiel P: Tissue microarray technique in evaluation of proliferative activity in invasive ductal breast cancer. Anticancer Res 32: 773-777, 2012.
36. Padmanabhan V, Callas P, Philips G, Trainer TD and Beatty BG: DNA replication regulation protein MCM7 as a marker of proliferation in prostate cancer. J Clin Pathol 57: 1057-1062, 2004.
37. Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Takeda K, Aburatani H, Oizumi S, Konishi J, Kaga K, Matsuno Y, Birrer MJ, Nishimura M and Dosaka-Akita H: Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer. Lung Cancer 72: 229-237, 2011.
38. Shen XX, Yu L, Bi R and Yang WT: Clinicopathologic study and immunohistochemistry comparison of PAX2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas. Zhonghua Bing Li Xue Za Zhi 40: 511-516, 2011.
39. Aune G, Stunes AK, Tingulstad S, Salvesen O, Syversen U and Torp SH: The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Int J Clin Exp Pathol 4: 444-453, 2011.
40. Zagorianakou N, Stefanou D, Makrydimas G, Zagorianakou P, Briasoulis E, Karavasilis V, Pavlidis N and Agnantis NJ: Clinicopathological study of metallothionein immuno-histochemical expression, in benign, borderline and malignant ovarian epithelial tumors. Histol Histopathol 21: 341-347, 2006.
41. McCluggage WG, Strand K and Abdulkadir A: Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors. Int J Gynecol Cancer 12: 62-65, 2002.
42. Werynska B, Pula B, Muszczynska-Bernhard B, Gomulkiewicz A, Jethon A, Podhorska-Okolow M, Jankowska R and Dziegiel P: Expression of metallothionein-III in patients with non-small cell lung cancer. Anticancer Res 33: 965-974, 2013.